<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00377949</url>
  </required_header>
  <id_info>
    <org_study_id>IRB # 04-227</org_study_id>
    <nct_id>NCT00377949</nct_id>
  </id_info>
  <brief_title>Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients</brief_title>
  <official_title>The Natural History and Outcome of Patients With Scleroderma at High Risk for or With Early Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the timeline of progression from pre-pulmonary
      hypertension to diagnosable pulmonary hypertension based on right heart catheterization.
      Moreover, to determine the timeline for progression from diagnosable pulmonary hypertension
      to clinical worsening of disease as defined as death, hospitalization, or worsening of PHT
      symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic sclerosis (SSc) is a rare, often fatal idiopathic disease, which has no effective
      therapy. One of the most major complications of systematic sclerosis is pulmonary
      hypertension (PHT), which is now the cause of all scleroderma related deaths. New therapeutic
      advances have improved short-term management of pulmonary hypertension in scleroderma, but
      long-term outcomes are unknown. With this in mind, Dr. Steen has developed Pulmonary
      Hypertension Assessment Registry of Scleroderma (PHAROS), a preventive, multi-center, web
      based observational study that looks at the natural history and outcome of scleroderma
      patients who are at high risk or have early pulmonary hypertension. Patients entered into the
      registry will be followed in prospective fashion noting the clinical course of disease by
      both scheduled and event driven follow up. A thorough baseline history will be collected to
      determine key prognostic and correlative factors for both disease prevalence and progression.
      Yearly follow up consisting of questionnaires, pulmonary function tests, echocardiogram, 6
      minute walk tests and predefined patient characteristics will also be conducted to further
      understand and note the progression of scleroderma related PAH. Event driven follow up will
      occur to record findings and record specific predetermined events in the clinical course of
      disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary Hypertension Progression</measure>
    <time_frame>10 years</time_frame>
    <description>The primary objective of the study is to determine the timeline of progression from pre-pulmonary hypertension to diagnosable pulmonary hypertension based on right heart catheterization</description>
  </primary_outcome>
  <enrollment type="Actual">602</enrollment>
  <condition>Systemic Sclerosis</condition>
  <condition>Scleroderma</condition>
  <condition>Pulmonary Hypertension</condition>
  <condition>Pulmonary Arterial Hypertension</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum stored for future analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care, rheumatology and pulmonary hypertension clinics.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. Global Inclusion Criteria

               -  Eligible patients must meet all of the following inclusion criteria:

               -  Patient ≥ 18 years with a clinical diagnosis of SSc (ACR criteria or the LeRoy
                  criteria for limited or diffuse scleroderma

          2. Specific Inclusion Criteria

               -  Diagnosis of &quot;pre&quot; pulmonary arterial hypertension defined as:

               -  Echocardiogram with a resting sPAP of ≥ 40mmHg Or

               -  Pulmonary function test with FVC &gt;70% and a DLCO &lt;55% of predicted or a FVC/DLco
                  ratio &gt;1.6. or

               -  Right heart catheterization which shows or a mean PA pressure &gt; 30mmHg with
                  exercise (with a mPAP &lt; 25mmHg at rest)

        Patients entered as a 'pre'-pulmonary arterial hypertension who then undergo right heart
        catheterization and are found to have pulmonary arterial hypertension, pulmonary venous
        hypertension or diastolic dysfunction or pulmonary hypertension secondary to interstitial
        lung disease will be followed as a definite PH patient and classified into the appropriate
        category.

          -  Diagnosis of definite pulmonary hypertension Patients with pulmonary hypertension with
             a right heart catheterization showing a mean PA pressure &gt; 25mmHg, diagnosed in the
             past 6 months.

        Classification of PH Group 1 PAH - Patients with mPAP ≥ 25mmHg with a wedge &lt; 15mmHg Group
        2 PVH - Patients who have a mean PA pressure ≥ 25mmHg with a wedge pressure which is &gt; 15
        mmHg Group 3 PH-ILD Patients who have a mean PA pressure ≥ 25mmHg (on right heart
        catheterization) who have moderate to severe interstitial fibrosis on HRCT scan with a FVC
        and TLC &lt; 65% predicted

        b. Exclusion Criteria

          -  Diagnosis and treatment of pulmonary hypertension for &gt; 6 months

          -  Patients with known severe interstitial fibrosis, pulmonary thrombotic disease, heart
             failure, cardiomyopathy,history of coronary artery disease or other cardio-pulmonary
             problems which could cause pulmonary hypertension are not eligible for the
             'pre'-pulmonary hypertension but do qualify for the definite pulmonary hypertension
             group if they have a right heart catheterization showing a mean PAH &gt;25mmHg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginia D. Steen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Medical and Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Science Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins University Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Medical School</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachussetts Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan-Scleroderma Program</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Medicine and Dentistry of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Rheumatology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Young RH, Mark GJ. Pulmonary vascular changes in scleroderma. Am J Med. 1978 Jun;64(6):998-1004.</citation>
    <PMID>148843</PMID>
  </reference>
  <reference>
    <citation>Salerni R, Rodnan GP, Leon DF, Shaver JA. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med. 1977 Apr;86(4):394-9.</citation>
    <PMID>848800</PMID>
  </reference>
  <reference>
    <citation>Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum. 1986 Apr;29(4):515-24.</citation>
    <PMID>3707629</PMID>
  </reference>
  <reference>
    <citation>Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn SD, Shortino D, Crow JW; Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 Feb 1;334(5):296-301.</citation>
    <PMID>8532025</PMID>
  </reference>
  <reference>
    <citation>Steen VD, Ziegler GL, Rodnan GP, Medsger TA Jr. Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum. 1984 Feb;27(2):125-31.</citation>
    <PMID>6607734</PMID>
  </reference>
  <reference>
    <citation>Murata I, Takenaka K, Yoshinoya S, Kikuchi K, Kiuchi T, Tanigawa T, Ito K. Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients. Chest. 1997 Jan;111(1):36-43.</citation>
    <PMID>8995990</PMID>
  </reference>
  <reference>
    <citation>Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol. 1997 Feb;36(2):239-43.</citation>
    <PMID>9133938</PMID>
  </reference>
  <reference>
    <citation>MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J, Black CM. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford). 2001 Apr;40(4):453-9.</citation>
    <PMID>11312386</PMID>
  </reference>
  <reference>
    <citation>Yousem SA. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol. 1990 May;21(5):467-74. Review.</citation>
    <PMID>2186993</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2006</study_first_submitted>
  <study_first_submitted_qc>September 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2006</study_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Georgetown University</investigator_affiliation>
    <investigator_full_name>Virginia Steen, MD</investigator_full_name>
    <investigator_title>Project Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Systemic Sclerosis</keyword>
  <keyword>Scleroderma</keyword>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>PHAROS</keyword>
  <keyword>PHROS</keyword>
  <keyword>Exercise Echocardiogram</keyword>
  <keyword>Pulmonary Functional Tests</keyword>
  <keyword>Six minute walk tests</keyword>
  <keyword>6 minute walk tests</keyword>
  <keyword>Right heart catheterization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

